Grifols, S.A. (BME: GRF)
Spain
· Delayed Price · Currency is EUR | Market Cap | 5.51B |
| Revenue (ttm) | 7.01B |
| Net Income (ttm) | 161.49M |
| Shares Out | 679.63M |
| EPS (ttm) | 0.24 |
| PE Ratio | 37.24 |
| Forward PE | 10.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,080,070 |
| Average Volume | 1,354,772 |
| Open | 8.88 |
| Previous Close | 8.89 |
| Day's Range | 8.83 - 8.93 |
| 52-Week Range | 6.36 - 12.04 |
| Beta | 0.68 |
| RSI | 40.17 |
| Earnings Date | Feb 28, 2025 |
About Grifols
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and... [Read more]
Financial Performance
In 2023, Grifols's revenue was 6.59 billion, an increase of 8.71% compared to the previous year's 6.06 billion. Earnings were 59.32 million, a decrease of -71.52%.
Financial StatementsNews
Grifols SA (GRFS) Partners with Michael J. Fox Foundation to Advance Parkinson's Disease Research
Grifols SA (GRFS) Partners with Michael J. Fox Foundation to Advance Parkinson's Disease Research
Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease
BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it h...
Mason Capital complains about Grifols' transparency to Spanish regulator
U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding more transparency from the embattled pharmaceutical company Grifols.
Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.5% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Short Seller Gotham Asks Judge to Toss Grifols Defamation Suit
US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA.
Grifols, S.A. 2024 Q3 - Results - Earnings Call Presentation
Grifols’ Annus Horribilis Has Analysts and Short Sellers Divided
Spanish drugmaker Grifols SA is poised for its worst year on record, but some analysts aren’t ready yet to give up on a stock that’s been a favorite target of short sellers.
Grifols Seeks to Calm Investors With €1.3 Billion Debt Placement
Grifols SA raised €1.3 billion ($1.4 billion) in a private debt placement, as the Spanish drugmaker seeks to reassure investors about its ability to manage borrowings.
Flat Footed Calls for Prompt Governance Overhaul at Grifols
BARCELONA, Spain--(BUSINESS WIRE)--Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed Series LLC - Fund 3, and GP Recovery Fund LLC (collectively, with Flat Footed LLC, “Flat Foot...
Grifols Names Two New Board Members in Win for Hedge Fund Mason
Grifols SA, the drugmaker reeling from a short-seller attack earlier this year, named two new board members, as it faces pressure from a group of small shareholders led by hedge fund Mason Capital Man...
Spain's market regulator sees signs of manipulation in Grifols-Gotham dispute
The outgoing head of Spain's stock market regulator CNMV, Rodrigo Buenaventura, told reporters on Thursday that there were signs of possible market manipulation in the dispute between short seller Got...
SEC Drops Probe Into Gotham Over Report on Grifols’ Accounts
The US dropped its investigation into General Industrial Partners LLP, the parent company of Gotham City Research, which accused drug maker Grifols SA of deceptive accounting earlier this year.
The High-Powered Lawyer Behind the Grifols Group’s Rise and Fall
For hedge fund Mason Capital Management LLC, much of what ails Grifols SA can be laid at the door of one man: Tomas Daga. But for the drugmaker, Daga is someone who’s helped transform the once-tiny Sp...
Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Statement From Araoz y Rueda on Behalf of Certain Institutional Investors in Grifols
MADRID--(BUSINESS WIRE)--Law firm Araoz y Rueda has been independently engaged by several international and Spanish institutions (the “Clients”) holding in aggregate 5.65% of A shares and 3.88% of B s...
Grifols Shareholder Mason Capital Calls for Board to Be Replaced
Mason Capital Management LLC’s Kenneth M Garschina said he wants Grifols SA’s board replaced.
Key deals this week: EnLink Midstream, Peabody, StoneCo, UniCredit and more
Stay updated on recent acquisitions in the financial sector with news on Grifols, Summit Materials, UniCredit, Peabody, and more.
Grifols: More Attractive Than In A Very Long Time
Grifols rejects Brookfield’s €10.5/share offer, signaling undervaluation. Read why GRFS stock is a strong "Buy" despite the current buyout bid.
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?
Grifols ends acquisition talks with Brookfield ... Full story available on Benzinga.com
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?
On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.
Grifols said to be in talks to restructure debt
Grifols (GRFS) stock in focus as company seeks to refinance bonds due in 2025 as Brookfield drops bid to take its private. Read more here.
Drugmaker Grifols’s ‘Problems Are Far From Over,’ Says Oddo
Grifols SA needs to focus on financial restructuring and address corporate governance issues to win over investors after Brookfield Asset Management ditched plans to buy the drugmaker, according to Od...
Grifols to Outline Standalone Strategy After Brookfield Drops $6.8 Billion Bid
Scott Bessent’s ultimate Trump trade
Plus, Brookfield drops deal for Spanish healthcare group Grifols and Sequoia Capital’s spun-off China unit hunts for global deals
Brookfield drops US$6.8-billion offer to buy drugmaker Grifols
Grifols board rejected the offer